The US FDA approved Wellcovorin (leucovorin calcium) tablets on March 10, 2026, for the treatment of cerebral folate deficiency in adult and pediatric patients with a confirmed variant in the FOLR1 gene. The decision makes leucovorin the first therapy cleared by the agency for this rare genetic condition, in which impaired folate transport into the brain leads to developmental delays, movement disorders, seizures, and other neurological complications. GSK holds the New Drug Application for Wellcovorin, and the US FDA collaborated with the company to update the drug's labeling to include the new indication.
The approval covers an expanded use of an established molecule. Leucovorin calcium has been available for decades, used primarily in oncology as a rescue agent after high-dose methotrexate and as a modulator of 5-fluorouracil. The new indication applies specifically to patients with cerebral folate transport deficiency caused by variants in the folate receptor 1 gene, designated CFD-FOLR1. The condition has an estimated prevalence of fewer than 1 in 100,000, placing it in the category of ultra-rare diseases. Prior to this approval, clinicians treated CFD-FOLR1 patients with off-label folinic acid guided by case reports and expert consensus, without a formally sanctioned therapeutic option.
The US FDA based its decision on a systematic review of published literature rather than conventional prospective clinical trials. The evidence included published case reports with patient-level information and mechanistic data demonstrating that leucovorin, a reduced folate, can bypass the defective FOLR1-mediated transport pathway and enter the central nervous system through alternative mechanisms such as the reduced folate carrier. Across the published cases, treatment was associated with normalization of cerebrospinal fluid 5-methyltetrahydrofolate levels, reductions in seizure frequency, and improvements in motor and cognitive function. Earlier treatment initiation correlated with better neurological outcomes. The agency noted that this approach to using real-world evidence provides a model for regulatory evaluation in ultra-rare diseases where randomized controlled trials are not feasible. Tracy Beth Hoeg, Acting Director of the US FDA's Center for Drug Evaluation and Research, said the approval "provides a good example of how observational or 'real world' evidence can lead to an FDA approval when the product is shown to provide clear clinical benefit compared with what is seen with the natural history of the disease." Possible side effects listed in the updated labeling include pruritus, rash, urticaria, dyspnea, rigors, impaired thermoregulation, and anaphylaxis.
The approval addresses a condition with no prior regulatory-sanctioned treatment, but unmet needs remain. Published case series indicate that some patients show incomplete neurological recovery on oral leucovorin, and long-term outcome data are limited given the small number of documented cases. The regulatory precedent set by the US FDA's reliance on literature-based evidence may influence how other candidates for this indication are evaluated. Several investigational approaches are in early-stage development, including intrathecal folinic acid formulations being studied at European academic centers, levoleucovorin in phase 2 evaluation, and an AAV9-FOLR1 gene therapy program at the Children's Hospital of Philadelphia and University of Pennsylvania that aims to restore functional folate receptor expression in the choroid plexus. None of these has advanced beyond early clinical stages, and the development landscape remains dominated by academic and investigator-initiated efforts rather than large pharmaceutical programs, a reflection of the disease's rarity and the small trial populations involved.
Spot something wrong? Report an issue with this article